7 hours ago
1
Shares of Prothena Corporation (NASDAQ:PRTA) lost ~31% to reach a new 52-week low on Tuesday after a late-stage trial for its lead asset, birtamimab, failed to reach the main goal in patients with a rare blood disorder called AL amyloidosis, prompting Oppenheimer and Jefferies
English (US) ·